The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Gusev E.I.

Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Current algorithms of diagnosis and treatment of multiple sclerosis based on the individual assessment of the patient

Authors:

Boĭko A.N., Gusev E.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2‑2): 92‑106

DOI: 10.17116/jnevro20171172292-106

Read: 10500 times

Download PDF (RU)
Contact the author
Table of contents

CURRENT ALGORITHMS OF DIAGNOSIS AND TREATMENT OF MULTIPLE SCLEROSIS BASED ON THE INDIVIDUAL ASSESSMENT OF THE PATIENT
CURRENT ALGORITHMS OF DIAGNOSIS AND TREATMENT OF MULTIPLE SCLEROSIS BASED ON THE INDIVIDUAL ASSESSMENT OF THE PATIENT

To cite this article:

Boĭko AN, Gusev EI. Current algorithms of diagnosis and treatment of multiple sclerosis based on the individual assessment of the patient. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2‑2):92‑106. (In Russ.)
https://doi.org/10.17116/jnevro20171172292-106

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
Clinical case of primary hype­raldosteronism dete­cted during pregnancy: differential diagnosis, neonatal prognosis. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):98-104
Diagnosis of pathological and adaptive bala­nce changes in Parkinson’s disease to select a reha­bilitation program. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):88-94
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Postoperative peri­tonitis: epidemiology, diagnosis, surgical treatment and prognosis. Piro­gov Russian Journal of Surgery. 2025;(6):104-111
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Abstract:

This review presents the current knowledge on diagnosis, therapy of relapses of multiple Sclerosis (MS) and disease-modifying therapy (DMT) in MS. Algorithms of diagnosis and therapy of MS are presented. Special attention is paid to the analysis of efficacy, tolerability and safety of DMT in MS.

Keywords:

multiple sclerosis
diagnosis
treatment algorithm

Authors:

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Gusev E.I.

Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Close metadata

References:

  1. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83(11):1022-1024. doi:10.1212/WNL.0000000000000768
  2. Flachenecker P, Buckow K, Pugliatti M, Kes VB, Battaglia MA, Boyko A, Confavreux C, Ellenberger D, Eskic D, Ford D, Friede T, Fuge J, Glaser A, Hillert J, Holloway E, Ioannidou E, Kappos L, Kasilingam E, Koch-Henriksen N, Kuhle J, Lepore V, Middleton R, Myhr KM, Orologas A, Otero S, Pitschnau-Michel D, Rienhoff O, Sastre-Garriga J, Schyns-Liharska T, Sutovic D, Thalheim C, Trojano M, Vlasov YV, Yaldizli O; EUReMS Consortium. Multiple sclerosis registries in Europe — results of a systematic survey. Mult Scler. 2014;20(11):1523-1532. doi:10.1177/1352458514528760
  3. Howard J, Trevick S, Younger DS. Epidemiology of Multiple Sclerosis. Neurol Clin. 2016;34(4):919-939. doi:10.1016/j.ncl.2016.06.016
  4. Boyko A, Smirnova N, Petrov S, Gusev E. Epidemiology of MS in Russia, a historical review. Multiple Sclerosis & Demyelinating Diseases. 2016;1:13. doi:10.1186/s40893-016-0016-9
  5. Boyko AN, Kukel TM, Lysenko MA, Vdovichenko TV, Gusev EI. Clinical epidemiology of multiple sclerosis in Moscow. Descriptive epidemiology in population of one region of Moscow. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2013;113:10(2):8-14. (In Russ.).
  6. Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannnoni G, Havrdová E, Hommes O, Kesselring J, Kobelt G, Langdon D, LeLorier J, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C. Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. Multiple Sclerosis & Related Disorders. 2015;4(3):202-218. doi:10.1016/j.msard.2015.02.005
  7. Sobocki P, Pugliatti M, Lauer K, Kobelt G. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler. 2007;13(8):1054-1064.
  8. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis Nat Rev Neurol. 2017;13(1):25-36. doi:10.1038/nrneurol.2016.187
  9. Kakalacheva K, Lünemann JD. Environmental triggers of multiple sclerosis. FEBS Lett. 2011;1:585(23):3724-3729. doi:10.1016/j.febslet.2011.04.006
  10. Popova EV, Boyko AN, Khachanova NV, Sharanova SN. Epstein-Barr virus in the pathogenesis of multiple sclerosis (a review). Zh Nevrol Psikhiatr Im S.S. Korsakova. 2014;114:2(2):29-34. (In Russ.).
  11. Boyko AN. Environmental and genetic risk factors and their role in ethiology, immunopathogenesis and clinic of multiple sclerosis. Materials of thesis on the degree of doctor of medical sciences. M. 1997.
  12. Lanzillo R, Carotenuto A, Moccia M, Saccà F, Russo CV, Massarelli M, De Rosa A, Brescia Morra V. A longitudinal real-life comparison study of natalizumab and fingolimod. Acta Neurol Scand. 2016. doi:10.1111/ane.12718
  13. Moccia M, Palladino R, Carotenuto A, Russo CV, Triassi M, Lanzillo R, Brescia Morra V. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis. Mult Scler Relat Disord. 2016;10:90-96. doi:10.1016/j.msard.2016.09.011
  14. Boyko A. Long-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observation. Multiple Sclerosis & Demyelinating Diseases. 2016;1:14. doi:10.1186/s40893-016-0015-x
  15. Tsareva E, Kulakova O, Boyko A, Favorova O. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs. Pharmacogenet Genomics. 2016;26(3):103-115. doi:10.1097/FPC.0000000000000194
  16. Kulakova OG, Tsareva EY, Lvovs D, Favorov AV, Boyko AN, Favorova OO. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate. Pharmacogenomics. 2014;15(5):679-685. doi:10.2217/pgs.14.26
  17. Belova AN, Boyko AN, Belova EM. Diagnostic criteria for neuromyelitisoptica spectrum disorders. Zh Nevrol Psikhiatr Im S.S.Korsakova. 2016;116:2(2):32-40. (In Russ.).
  18. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2016. doi:10.1056/NEJMoa1606468
  19. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. doi:10.1002/ana.22366
  20. Belova AN, Shalenkov IV, Shakurova DN, Boyko AN. Revised McDonald criteria for multiple sclerosis diagnostics in central Russia: sensitivity and specificity. Mult Scler. 2014;20(14):1896-1899. doi:10.1177/1352458514539405
  21. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F. MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15(3):292-303. doi:10.1016/S1474-4422(15)00393-2
  22. Samaraweera AP, Clarke MA, Whitehead A, Falah Y, Driver ID, Dineen RA, Morgan PS, Evangelou N. The Central Vein Sign in Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. J Neuroimaging. 2017;27(1):114-121. doi:10.1111/jon.12367
  23. Lebrun C. The radiologically isolated syndrome. Rev Neurol. 2015;171(10):698-706. doi:10.1016/j.neurol.2015.05.001 Bryukhov VV, Popova EV, Krotenkova IA, Boyko AN. Radiologically isolated syndrome — MRI criteria and management tactics. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2016;10(2):52-57. (In Russ.).
  24. Brownlee WJ, Miller DH. Clinically isolated syndromes and the relationship to multiple sclerosis. J Clin Neurosci. 2014;21(12):2065-2071. doi:10.1016/j.jocn.2014.02.026
  25. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286. doi:10.1212/WNL.0000000000000560
  26. Boyko AN. Recommendations for the use of fingolimod (Gilenia). Medizidskyi sovet. 2012;4:3-10. (In Russ.).
  27. Sidorenko TV, Kol'iak EV, Boyko AN. Natalizumab: a new way for MS treatment. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2009;109:7(2):122-128. (In Russ.).
  28. Khasaeva MA, Gorokhova TV, Boĭko AN, Gusev EI. Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2013;113:2(2):87-92. (In Russ.).
  29. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O’Neill G, Elkins J. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Eng J Med. 2015;373:15:1418-1428. doi:10.1056/NEJMoa1501481
  30. Schumacher GA. Critique of experimental trials of therapy in multiple sclerosis. Neurology. 1974;24(11):1010-1014.
  31. Repovic P, Lublin FD. Treatment of multiple sclerosis exacerbations. Neurol Clin. 2011;2:389-400. doi:10.1016/j.ncl.2010.12.012
  32. Criteria of non-efficacy of treatment and withdrawal of first line DMD and switching to second-line drugs. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2015;115:8(2):44.
  33. Popova EV, Kukel' TM, Muravin AI, Boĭko AN, Murashko AV, Gusev EI. Pregnancy and delivery in women with multiple sclerosis: a retrospective analysis. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2013;113:10(2):52-56. (In Russ.).
  34. Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing — Remitting Multiple Sclerosis. Adv Ther. 2014;31(11):1134-1154. doi:10.1007/s12325-014-0167-z
  35. Bevan CJ, Cree BA Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 2014;71:269-270. doi:10.1001/jamaneurol.2013.5486
  36. Kappos L, De Stefano N, Freedman MS, Cree BAC, Radue E-W, Sprenger T, Sormani MP, Smith T, Häring DA, Meier DP, Tomic D. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing — remitting multiple sclerosis. Mult Scler. 2016;22(10):1297-1305. doi:10.1177/1352458515616701
  37. Edan G, Le Page E Induction Therapy for Patients with Multiple Sclerosis: Why? When? How? CNS Drugs. 2013;27(6):403-409. doi:10.1007/s40263-013-0065-y
  38. Boyko AN, Davydovskaia MV, Demina TL, Lashch NIu, Ovcharov VV, Popova EV, Popova NF, Romashkin AV, Boĭko OV, Khachanova NV, Sharanova SN, Shchur SG, Gusev EI.Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2012;112:2(2):86-92.
  39. Boyko A. Long-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observation. Multiple Sclerosis & Demyelinating Diseases. 2016;1:14. doi:10.1186/s40893-016-0015-x
  40. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73(6):705-713. doi:10.1002/ana.23938
  41. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A. Pegylated interferon beta-1a in relapsing-remitting multiple sclerosis (ADVANCE): a randomized, phase 3, double-blind study. Lancet Neurol. 2014;13(7):657-665. doi:10.1177/1352458514557986
  42. Popova EV, Boyko AN, Davydovskaia MV, Demina TL, Kukel' TM, Lashch NIu, Popova NF, Khachanova NV, Shchur SG, Gusev EI. The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2013;113:10(2):93-96. (In Russ.).
  43. Borets OG, Davydovskaia MV, Demina TL, Lashch NIu, Popova NF, Popova EV, Khachanova NV, Khasaeva MV, Shchur SG, Boyko AN. Experience of using interferon Β-1a biosimilars (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2015;115:2(2):51-56. (In Russ.).
  44. Kasatkin DS, Spirin NN, Boyko AN, Stepanov IO, Spirina NN, Baranova NS. The results of an open prospective study of β-interferon biosimilars. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2016;116:2( 2):68-73. (In Russ.).
  45. Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263(6):1053-1065. doi:10.1007/s00415-015-7986-y
  46. Paolicelli D, Manni A, Iaffaldano A, Di Lecce V, D'Onghia M, Iaffaldano P, Trojano M The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study. Eur J Clin Pharmacol. 2016;72(8):1025-1029. doi:10.1007/s00228-016-2073-6
  47. Sørensen PS .Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox. Mult Scler. 2012;18(2):131-132. doi:10.1177/1352458511419438
  48. Boyko OV, Stoliarov ID, Petrov AM, Boyko AN. Teriflunomide is a new peroral disease-modifying drug for multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113:10(2):78-81. (In Russ.).
  49. O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS. Teriflunomide Multiple Sclerosis Oral (TEMSO) Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86(10):920-930. doi:10.1212/WNL.0000000000002441
  50. Confavreux C, O’Connor P, Comi G et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247-256. doi:10.1016/S1474-4422(13)70308-9
  51. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-1107. doi:10.1056/NEJMoa1114287
  52. Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther Adv Chronic Dis. 2016;7(4):198-207. doi:10.1177/2040622316653307
  53. Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurol Ther. 2016;5(1):45-57. doi:10.1007/s40120-016-0042-8
  54. Lehmann-Horn K, Penkert H, Grein P, Leppmeier U, Teuber-Hanselmann S, Hemmer B, Berthele A. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? Neurology. 2016;87(4):440-441. doi:10.1212/WNL.0000000000002900
  55. Fazekas F. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr. 2012;162(15-16):354-366. doi:10.1007/s10354-012-0123-y
  56. Pfender N, Jelcic I, Linnebank M, Schwarz U, Martin R. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis. Neurology. 2015;84(23):2377-2378. doi:10.1212/WNL.0000000000001659
  57. Harrer A, Wipfler P, Pilz G, Oppermann K, Haschke-Becher E, Afazel S, Kraus J, Trinka E, Sellner J Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod. Int J Mol Sci. 2015;16(9):21832-21845. doi:10.3390/ijms160921832
  58. Fonseca J. Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice. Neurosci J. 2015;389360. doi:10.1155/2015/389360
  59. Popova EV, Boyko AN, Boyko OV. The results of a randomized, open, multicenter, comparative study on the tolerability and safety of gilenya (fingolimod) in patients with remitting multiple sclerosis (GIMN) Zh Nevrol Psikhiatr Im S.S. Korsakova. 2015;115:2(2):45-50. (In Russ.).
  60. Popova EV, Jalimov A, Boyko AN, Davidovskaya MV, Koliak EV, Traktirskaya OV, Khachanova NV, Schur SG. Fingolimod in treatment of multiple sclerosis: experience in Moscow MS Center. Medizidskyi sovet. 2014;3:50-52. (In Russ.).
  61. Sorensen P, Bertolotto A, Edan G et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis Journal. 2012;18(2):143-152. doi:10.1177/1352458511435105
  62. McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson O R, Rog D, Young CA Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87(2):117-125. doi:10.1136/jnnp-2015-311100
  63. Popova EV, Boyko AN, Davidovskaya MV, Boyko OV, Khachanova NV. Natalizumab in the therapy of multiple sclerosis. Experience at the Moscow MS Center. Medizidskyi sovet. 2014;10:52-54.
  64. Boyko AN, Evdoshenko EP, Vorob’eva OV, You X, Pukaite V. A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2015;115:8(2):25-35. (In Russ.).
  65. Sivertseva SA, Levitina EV, Trajkhil AM, Zakatey IG, Bazhukhin DV, Sivertsev MY, Smirnova NF, Boyko AN. The First Experience of Natalizumab Therapy for Relapsing Remitting Pediatric Multiple Sclerosis in Russia. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2014;114:10(2):92-98. (In Russ.).
  66. Hartung HP, Aktas O, Boyko AN. Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis. Multiple sclerosis Journal. 2015;21(1):22-34. doi:10.1177/1352458514549398
  67. Coles AJ, Boyko AN, Cohen JA, De Seze J, Fox EJ, Havrdova E, Hartung H-P, Inshasi JS, McCombe P, Selmaj KW, Vermersch P, Van Wijmeersch B, Margolin DH, Thangavelu K, Rodriguez CE, Montalban X. On behalf of the CARE-MS I Investigators. Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsingremitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I). Multiple Sclerosis Journal. 2016;22:(3):75-76. doi:10.1177/1352458516663068
  68. Boyko AN, Barnett M, Brassat D, Dive D, Hupperts RMM, Lycke J, Montalban X, Sharrack B, Wray S, Margolin DH, Thangavelu K. Chirieac M, Wiendl H. On behalf of the CARE-MS II Investigators. Alemtuzumab improves clinical outcomes over 4 years in patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a: CARE-MS II extension study 4-year follow-up. Multiple Sclerosis Journal. 2016;22:(3):326-327.
  69. Bielekova B. Daclizumab Therapy for Multiple Sclerosis. Neurotherapeutics. 2013;10(1):55-67. doi:10.1007/s13311-012-0147-4
  70. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O’Neill G, Elkins J. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Eng J Med. 2015;373:15:1418-1428.
  71. Milo R. The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. Ther Adv Neurol Disord. 2014;7(1):7-21. doi:10.1177/1756285613504021
  72. Gusev EI, Zavalishin IA, Boyko AN. Multiple sclerosis. Clinical guidelines. M.: Real-time; 2011. (In Russ.).
  73. Fox E, Edwards K, Burch G, Wynn DR, LaGanke C, Crayton H, Hunter SF, Huffman C, Kim E, Pestreich L, McCague K, Barbato L. EPOC study investigators Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord. 2014;3(5):607-619. doi:10.1016/j.msard.2014.06.005
  74. Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263:1053-1065. doi:10.1007/s00415-015-7986-y
  75. Rio J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. 2009;5:553-560. doi:10.1038/nrneurol.2009.139
  76. Sormani MP, Rio J, Tintore M, Signori A, Li D, Cornelisse P. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013;19:605-612. doi:10.1177/1352458512460605
  77. Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, Morgenthau D, Lapierre Y. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013;40(3):307-323.
  78. Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Mult Scler. 2016;22(10):1315-1326.
  79. Tsivgoulis G, Katsanos AH, Mavridis D, Grigoriadis N, Dardiotis E, Heliopoulos I, Papathanasopoulos P, Karapanayiotides T, Kilidireas C, Hadjigeorgiou GM, Voumvourakis K; The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials. PLoS One. 2016;11(9):0163296. doi:10.1371/journal.pone.0163296
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.